Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
deathknight
deathknight Sep. 9 at 12:56 PM
$AFMD at this point, I only hope they can at least have the decency to give us a closure. Even that might be too much of an ask.
0 · Reply
Think_Bigly
Think_Bigly Sep. 8 at 2:42 PM
$AFMD BRIEF-Artiva Biotherapeutics Provides Update On Planned Allonk® Data Disclosures And Development Milestones For The Remainder Of 2026 Now they can announce their 2nd target disease. AFM-13 is their straightest line to revenue and value since they already own 33% of the combo in HodgkinsL.
0 · Reply
deathknight
deathknight Sep. 5 at 4:49 PM
$AFMD New post from Bruker. Guess we all know where did he get his "inside" experience from...
2 · Reply
Think_Bigly
Think_Bigly Sep. 2 at 8:55 PM
$AFMD ARTV says they have all needed $$ to fund their second target.. which they will choose in 2026. Gilde on AFM-13: The company’s lead product candidate has demonstrated transformational data in patients suffering from end-stage Hodgkin’s lymphoma... Affimed has the potential to lead a paradigm shift in oncology by offering a life-changing new treatment option for thousands of patients.
0 · Reply
Think_Bigly
Think_Bigly Sep. 2 at 7:47 PM
$AFMD Brave AI- AFM24 is not part of the partnership between Affimed and Artiva Biotherapeutics; the collaboration specifically covers AFM13 (acitamig). Under the agreement, Affimed receives 67% of the combination therapy revenues, while Artiva receives 33%. AFM13 Partnership: The 67/33 revenue split applies strictly to the AFM13/AB-101 combination for CD30-positive lymphomas. AFM24 Status: AFM24 is a separate Affimed program targeting EGFR-expressing solid tumors and is not included in the Artiva co-exclusive development rights. Commercial Strategy: The 67/33 split for AFM13 has been noted as a challenge for Affimed’s broader partnering efforts, as it retains only one-third of the economics for the partnered asset.
0 · Reply
Hodl707
Hodl707 Aug. 27 at 6:50 PM
$AFMD they are showing some thing but nothing not sure what this means but no longer what it use to be
0 · Reply
Hodl707
Hodl707 Aug. 25 at 5:35 PM
$AFMD some one just looked at my profile
1 · Reply
Hodl707
Hodl707 Aug. 25 at 2:25 AM
$AFMD this is getting really good his post !!
1 · Reply
deathknight
deathknight Aug. 24 at 5:29 PM
$AFMD This patent: EP3843757 is a very broad method patent that covers ANY antibodies being used in an over-the-shelf, pre-complexed NK therapeutic product. The patent was granted in 2024 and is active through 2039. $AFMD themselves showed in the same year, that the best way to use NK therapy is to pre-complex an engager (AFM13) with NK cells (Artiva's AB101). Any NK therapy company without Affimed's license is essentially shut out of the over-the-shelf option which is the biggest advantage of NK therapy over CAR-T. This is a huge IP moat that dwarfs even their stellar ICE molecules.
2 · Reply
Hodl707
Hodl707 Aug. 24 at 1:07 AM
$AFMD https://synapse.patsnap.com/blog/bd-opportunity-scan-affimed-n-v-2026-mcp? Take a look at this guys read this asap !!
1 · Reply
Latest News on AFMD
No data available.
deathknight
deathknight Sep. 9 at 12:56 PM
$AFMD at this point, I only hope they can at least have the decency to give us a closure. Even that might be too much of an ask.
0 · Reply
Think_Bigly
Think_Bigly Sep. 8 at 2:42 PM
$AFMD BRIEF-Artiva Biotherapeutics Provides Update On Planned Allonk® Data Disclosures And Development Milestones For The Remainder Of 2026 Now they can announce their 2nd target disease. AFM-13 is their straightest line to revenue and value since they already own 33% of the combo in HodgkinsL.
0 · Reply
deathknight
deathknight Sep. 5 at 4:49 PM
$AFMD New post from Bruker. Guess we all know where did he get his "inside" experience from...
2 · Reply
Think_Bigly
Think_Bigly Sep. 2 at 8:55 PM
$AFMD ARTV says they have all needed $$ to fund their second target.. which they will choose in 2026. Gilde on AFM-13: The company’s lead product candidate has demonstrated transformational data in patients suffering from end-stage Hodgkin’s lymphoma... Affimed has the potential to lead a paradigm shift in oncology by offering a life-changing new treatment option for thousands of patients.
0 · Reply
Think_Bigly
Think_Bigly Sep. 2 at 7:47 PM
$AFMD Brave AI- AFM24 is not part of the partnership between Affimed and Artiva Biotherapeutics; the collaboration specifically covers AFM13 (acitamig). Under the agreement, Affimed receives 67% of the combination therapy revenues, while Artiva receives 33%. AFM13 Partnership: The 67/33 revenue split applies strictly to the AFM13/AB-101 combination for CD30-positive lymphomas. AFM24 Status: AFM24 is a separate Affimed program targeting EGFR-expressing solid tumors and is not included in the Artiva co-exclusive development rights. Commercial Strategy: The 67/33 split for AFM13 has been noted as a challenge for Affimed’s broader partnering efforts, as it retains only one-third of the economics for the partnered asset.
0 · Reply
Hodl707
Hodl707 Aug. 27 at 6:50 PM
$AFMD they are showing some thing but nothing not sure what this means but no longer what it use to be
0 · Reply
Hodl707
Hodl707 Aug. 25 at 5:35 PM
$AFMD some one just looked at my profile
1 · Reply
Hodl707
Hodl707 Aug. 25 at 2:25 AM
$AFMD this is getting really good his post !!
1 · Reply
deathknight
deathknight Aug. 24 at 5:29 PM
$AFMD This patent: EP3843757 is a very broad method patent that covers ANY antibodies being used in an over-the-shelf, pre-complexed NK therapeutic product. The patent was granted in 2024 and is active through 2039. $AFMD themselves showed in the same year, that the best way to use NK therapy is to pre-complex an engager (AFM13) with NK cells (Artiva's AB101). Any NK therapy company without Affimed's license is essentially shut out of the over-the-shelf option which is the biggest advantage of NK therapy over CAR-T. This is a huge IP moat that dwarfs even their stellar ICE molecules.
2 · Reply
Hodl707
Hodl707 Aug. 24 at 1:07 AM
$AFMD https://synapse.patsnap.com/blog/bd-opportunity-scan-affimed-n-v-2026-mcp? Take a look at this guys read this asap !!
1 · Reply
deathknight
deathknight Aug. 18 at 7:54 PM
$AFMD it's just me or Google search can no longer pull the website (the parking page still can be accessed directly) and snippet out?
1 · Reply
Think_Bigly
Think_Bigly Aug. 17 at 9:12 PM
$AFMD A good thing if ARTV takes this out: $50M+ BO or Reverse Merger. ARTV knows the platform and the MOA, so putting them in the same lab will benefit everyone.. especially patients.
0 · Reply
Hodl707
Hodl707 Aug. 17 at 4:43 PM
$AFMD This behavior perfectly aligns with your theory about Gilde Healthcare protecting their portfolio. A venture capital firm backing a high-value asset wants to avoid looking like they oversaw a chaotic failure. They keep top operational talent like Bruker financially incentivized and active so that the transition looks like a sophisticated, managed corporate evolution rather than an abrupt shutdown.
0 · Reply
Hodl707
Hodl707 Aug. 17 at 4:34 PM
$AFMD They Benefit Only If Shareholders Benefit: Because Gilde Healthcare holds equity (shares) rather than just traditional senior secured bank loans, their financial interests are structurally aligned with yours. For Gilde to make a profit on their remaining position, the final valuation of the IP must exceed the estate's liabilities to trigger a residual distribution to the share tier.
0 · Reply
Hodl707
Hodl707 Aug. 15 at 7:40 PM
$AFMD read his new post this exactly the kind of thing that makes Affimed super valuable!!
1 · Reply
deathknight
deathknight Aug. 15 at 4:46 PM
$AFMD a couple new discoveries on this: 1. While they direct all traffics to their website to Godaddy name server (the page we normally see), their real domain is hosted by AWS global accelerator -- a much more comprehensive and costly option than Godaddy; 2. According to Whoisfreak, the domain was initially hosted on IONOS, which I 100% sure was when their website was running on WordPress platform. The record now shows the hosting service has been transferred to AWS on Aug 11th -- literally a few days ago. Seems the Godaddy page is only meant to mask the true webpage before it's ready.
1 · Reply
Chund
Chund Aug. 7 at 11:18 PM
$AFMD right so we’re resorting to generic delusional bull vs bear racist arguments because you don’t like what I say, and akin to most on here, don’t have the intelligence to offer any form of actual rebuttal. This company is cooked and retail is blinded by the hype
2 · Reply
deathknight
deathknight Aug. 5 at 2:54 PM
$AFMD seems the website was pulled off soon after you sent the post but it does seem to be captured by google algorithm and thus the snippet is still showing. The AI search bot of google shows this website screen too (see below). Let's wait and see what will happen in the coming days/weeks -- seems some updates are coming.
2 · Reply
Hodl707
Hodl707 Aug. 4 at 1:05 AM
$AFMD if the administrator reactivated the account domain, it could most certainly be that might be in an announcement. I’m a little skeptical to think this is true since this website looks exactly like http://theusa.com one, but I’m also optimistic. Hopefully, we hear something.
0 · Reply
Hodl707
Hodl707 Aug. 3 at 11:31 PM
$AFMD don’t know what to think of this but this could be true idk someone could have just put that !!
0 · Reply
Hodl707
Hodl707 Aug. 3 at 11:20 PM
$AFMD @deathknight check this out guys !!
1 · Reply
Hodl707
Hodl707 Jul. 20 at 4:37 PM
$AFMD yup and of course tried to sell it’s not happen it was a glitch in the matrix!!
0 · Reply